Drugs / Unmanipulated UCB Unit
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1/2 | NCT00963872 Background | Mar 2010 → Aug 2012 | leukemia, myelodysplastic syndrome, plasma cell myeloma | Masonic Cancer Center, University of Minnesota | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Unmanipulated UCB Unit | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00963872 ↗ |
| Modality | Cell therapy | “unmanipulated UCB transplantation” NCT00963872 ↗ |
| Route | Intravenous | “the unmanipulated UCB unit will be infused FIRST through a central line” NCT00963872 ↗ |